Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 2016;35(5):723–34.
Wells MW. The Seasonal Patterns of Measles and Chicken Pox. Am J Hyg. 1944;40(3):279–317.
Yawn BP, Gilden D. The Global Epidemiology of Herpes Zoster. Neurology. 2013;81:928–30.
Sengupta N, Brewer J. A global perspective of the epidemiology and burden of varicella-zoster virus. Curr Pediatr Rev. 2009;5(4):207–28.
WHO. Background Paper on Varicella Vaccine: SAGE Working Group on Varicella and Herpes Zoster Vaccines. 2014. http://www.who.int/immunization/sage/meetings/2014/april/1_SAGE_varicella_background_paper_FINAL.pdf. Accessed 15 Sept 2015.
Thomas S, Hall A. What does epidemiology tell us about risk factors for herpes zoster? Lancet. 2001;4:26–33.
Donahue JG, Choo PW, Manson JE, Platt R. The Incidence of herpes zoster. Arch Intern Med. 1995;155:1605–9.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.
Vugia DJ, Peterson CL, Meyers HB, Kim KS, Arrieta A, Schlievert PM, et al. Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J. 1996;15(2):146–50.
Hope-Simpson R. The Nature of Herpes Zoster: A Long Term Study and a new Hypothesis. Proc R Soc Med. 1965;58:9–20.
Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360(9334):678–82.
Brisson M, Gay N, Edmunds W, Andrews N. Exposure to varicella boosts immunity to herpes zoster: implications for mass vaccination against chicken pox. Vaccine. 2002;20:2500–7.
Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, Leven M, et al. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunol. 2011;24:151–7.
Ogunjimi B, Smits E, Heynderickx S, Van den Bergh J, Bilcke J, Jansens H, et al. Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol. 2014;21(3):417–26.
Forbes H, Douglas I, Finn A, Breuer J, Bhaskaran K, Smeeth L, et al. Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data. BMJ. 2020;368:l6987. https://doi.org/10.1136/bmj.l6987.
Brisson M, Edmunds W, Gay N. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(S1):S31–7.
Guess H, Broughton D. Melton Lr, Kurland L. Population-based studies of varicella complications Pediatrics. 1986;78(4):723–7.
Preblud SR. Age-specific risks of varicella complications. Pediatrics. 1981;68(1):14–7.
Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5):S58–61.
Dai B, Chen Z, Liu Q, Wu T, Guo C, Wang X, et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health Organ. 1991;69(4):415.
CDC. Conducting Varicella Surveillance. 2015. http://www.cdc.gov/chickenpox/hcp/conducting-surveillance.html. Accessed 9/9/15.
Marinelli I, van Lier A, de Melker H, Pugliese A, van Boven M. Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus. Epidemics. 2017;19:1–12.
van Lier A, Lugnér A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, et al. Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster. EBioMedicine. 2015;2(10):1494–9.
Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:3332–40.
Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998 2003. BMC Publ Health. 2005;5(1):68.
Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine. 2013;31:1680–94.
Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis. 2005;191(12):2002–7.
Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122:e744–51.
Brisson M, Edmunds W, Gay BLBNJ, Walld R, Brownell M, Roos LL, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305-14.
Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135:908–13.
Ragozinno MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-Based Study of Herpes Zoster and Its Sequelae. Medicine. 1982;61(5):310–6.
Bakker KM, Martinez-Bakker M, Helm B, Stevenson TJ. Digital epidemiology reveals global childhood disease seasonality and the effects of immunization. Proc Natl Acad Sci U S A. 2016;113:6689–94.
Marziano V, Poletti P, Guzzetta G, Ajelli M, Manfredi P, Merler S. The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study. Proc R Soc B Biol Sci. 2015;282:20142509.
Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008;82:1448–57.
Zhong J, Rist M, Cooper L, Smith C, Khanna R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PloS ONE. 2008;3:e3256.
Coleman JL, Shukla D. Recent advances in vaccine development for herpes simplex virus types I and II. Human Vaccines and Immunotherapeutics. 2013;9:729–35.
Bakker KM, Eisenberg MC, Woods R, Martinez ME. Exploring the Seasonal Drivers of Varicella Zoster Virus Transmission and Reactivation. Am J Epidemiol. 2021;190(9):1814–20.
WHO. WHO webpage of country level annual vaccine uptake estimates. 2017. http://who.int/immunization.
Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. J Am Med Assoc. 2002;287(5):606–11.
Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature. 1985;318(6044):323.
Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302.
Gastañaduy PA, Budd J, Fisher N, Redd SB, Fletcher J, Miller J, et al. A measles outbreak in an underimmunized Amish community in Ohio. N Engl J Med. 2016;375(14):1343–54.
PHW. Shingles Immunisation Uptake Data for Wales. Public Health Wales. 2017. https://public.tableau.com/profile/public.health.wales.vpd.and.respiratory.surveillance.group#!/vizhome/NationalandHBlevelShinglesdashboard-ENGLISH/DBShinglesuptake-ENGLISH.
PHE. Herpes zoster (shingles) immunisation programme 2013/2014 for England. Public Health England. 2014. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/771129/ShinglesReport2014.pdf.
PHNI. Annual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland. Public Health Agency. 2017. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/771129/ShinglesReport2014.pdf.
Ogunjimi B, Willem L, Beutels P, Hens N. Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster. Elife. 2015;4:e07116.
Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother. 2004;5(3):551–9.
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;1481-6.
Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–4.
Hope-Simpson R. Postherpetic neuralgia. JR Coll Gen Pract. 1975;25(157):571–5.
Thai-Government. National Disease Surveillance. Bureau of Epidemiology. 2015. http://www.boe.moph.go.th/boedb.
Thai-NSO. National Statistical Office, 2010 Census. National Statistical Office of Thailand. 2013. http://www.nso.go.th/sites/2014en. Accessed 6 Dec 2019.
UN. United Nations Department of Economic and Social Affairs. United Nations. 2019. https://population.un.org/wpp/Download/Probabilistic/Fertility/. Accessed 11 May 2020.
Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S. The effectiveness of varicella vaccine in China. Pediatr Infect Dis J. 2010;29(8):690–3.
Marin M, Marti M, Kambhampati A, Jeram SM, Seward JF. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics. 2016;137(3):e20153741.
Vázquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291(7):851–5.
Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356(11):1121–9.
CDC. About the Varicella Vaccine. 2020. https://www.cdc.gov/vaccines/vpd/varicella/hcp/about-vaccine.html. Accessed 11 May 2020.
Lu P-J, O’Halloran A, Williams WW, Harpaz R. National and state-specific shingles vaccination among adults aged over 60 years. Am J Prev Med. 2017;52(3):362–72.
CDC. Zostovax. 2020. https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html. Accessed 11 May 2020.
King AA, Nguyen D, Ionides EL. Statistical Inference for Partially Observed Markov Processes via the R Package pomp. J Stat Softw. 2016;69(12):1–43.
